How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? a Bayesian design

Andre C Kalil, Junfeng Sun

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Controversies concerning the pivotal trial and negative results from other Drotrecogin alfa activated (DAA) trials have raised questions about its efficacy in severe sepsis patients. Based on all available evidence, our study aimed to respond to: (1) What is the current probability that DAA is not better than the control? If the current probability is not small, e.g. greater than 0.05, then (2) How many patients will be needed for the DAA confirmatory trial? Design: We applied the Bayesian methodology to all randomized trials which tested anti-thrombotic therapies for severe sepsis. Prior distributions were defined as severe skeptic (all anti-thrombotic trials or DAA trials); moderate skeptic (anti-thrombotic trials with high risk of death); mild skeptic (DAA trials only); enthusiastic (DAA trials with high risk of death). Results: The total study sample includes 7,683 patients: DAA (N = 3,143); Anti-thrombin-III (N = 2,581); tissue factor pathway inhibitor (N = 1,959). Answer 1: All current probabilities that DAA is not better than the control (except for the enthusiastic analysis) range from 0.14 to 0.48, which strongly suggest the need for a confirmatory trial. Answer 2: The number of patients necessary for the DAA confirmatory trial ranges up to 8,350 for the severe skeptic; 730-810 for moderate skeptic; 550-685 for mild skeptic; and zero for enthusiastic analysis. Conclusions: A confirmatory trial with approximately 600 patients with severe sepsis and high risk of death can provide a convincing answer for both the mild and moderate skeptic physicians concerning the efficacy of DAA in severe sepsis.

Original languageEnglish (US)
Pages (from-to)1804-1811
Number of pages8
JournalIntensive Care Medicine
Volume34
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Sepsis
drotrecogin alfa activated
Thrombin
Physicians

Keywords

  • Bayesian methodology
  • Drotrecogin alfa activated
  • Severe sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? a Bayesian design. / Kalil, Andre C; Sun, Junfeng.

In: Intensive Care Medicine, Vol. 34, No. 10, 01.10.2008, p. 1804-1811.

Research output: Contribution to journalArticle

@article{d618ae9d3c8d41f5a987afb5e87ceb06,
title = "How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? a Bayesian design",
abstract = "Objectives: Controversies concerning the pivotal trial and negative results from other Drotrecogin alfa activated (DAA) trials have raised questions about its efficacy in severe sepsis patients. Based on all available evidence, our study aimed to respond to: (1) What is the current probability that DAA is not better than the control? If the current probability is not small, e.g. greater than 0.05, then (2) How many patients will be needed for the DAA confirmatory trial? Design: We applied the Bayesian methodology to all randomized trials which tested anti-thrombotic therapies for severe sepsis. Prior distributions were defined as severe skeptic (all anti-thrombotic trials or DAA trials); moderate skeptic (anti-thrombotic trials with high risk of death); mild skeptic (DAA trials only); enthusiastic (DAA trials with high risk of death). Results: The total study sample includes 7,683 patients: DAA (N = 3,143); Anti-thrombin-III (N = 2,581); tissue factor pathway inhibitor (N = 1,959). Answer 1: All current probabilities that DAA is not better than the control (except for the enthusiastic analysis) range from 0.14 to 0.48, which strongly suggest the need for a confirmatory trial. Answer 2: The number of patients necessary for the DAA confirmatory trial ranges up to 8,350 for the severe skeptic; 730-810 for moderate skeptic; 550-685 for mild skeptic; and zero for enthusiastic analysis. Conclusions: A confirmatory trial with approximately 600 patients with severe sepsis and high risk of death can provide a convincing answer for both the mild and moderate skeptic physicians concerning the efficacy of DAA in severe sepsis.",
keywords = "Bayesian methodology, Drotrecogin alfa activated, Severe sepsis",
author = "Kalil, {Andre C} and Junfeng Sun",
year = "2008",
month = "10",
day = "1",
doi = "10.1007/s00134-008-1159-8",
language = "English (US)",
volume = "34",
pages = "1804--1811",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? a Bayesian design

AU - Kalil, Andre C

AU - Sun, Junfeng

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objectives: Controversies concerning the pivotal trial and negative results from other Drotrecogin alfa activated (DAA) trials have raised questions about its efficacy in severe sepsis patients. Based on all available evidence, our study aimed to respond to: (1) What is the current probability that DAA is not better than the control? If the current probability is not small, e.g. greater than 0.05, then (2) How many patients will be needed for the DAA confirmatory trial? Design: We applied the Bayesian methodology to all randomized trials which tested anti-thrombotic therapies for severe sepsis. Prior distributions were defined as severe skeptic (all anti-thrombotic trials or DAA trials); moderate skeptic (anti-thrombotic trials with high risk of death); mild skeptic (DAA trials only); enthusiastic (DAA trials with high risk of death). Results: The total study sample includes 7,683 patients: DAA (N = 3,143); Anti-thrombin-III (N = 2,581); tissue factor pathway inhibitor (N = 1,959). Answer 1: All current probabilities that DAA is not better than the control (except for the enthusiastic analysis) range from 0.14 to 0.48, which strongly suggest the need for a confirmatory trial. Answer 2: The number of patients necessary for the DAA confirmatory trial ranges up to 8,350 for the severe skeptic; 730-810 for moderate skeptic; 550-685 for mild skeptic; and zero for enthusiastic analysis. Conclusions: A confirmatory trial with approximately 600 patients with severe sepsis and high risk of death can provide a convincing answer for both the mild and moderate skeptic physicians concerning the efficacy of DAA in severe sepsis.

AB - Objectives: Controversies concerning the pivotal trial and negative results from other Drotrecogin alfa activated (DAA) trials have raised questions about its efficacy in severe sepsis patients. Based on all available evidence, our study aimed to respond to: (1) What is the current probability that DAA is not better than the control? If the current probability is not small, e.g. greater than 0.05, then (2) How many patients will be needed for the DAA confirmatory trial? Design: We applied the Bayesian methodology to all randomized trials which tested anti-thrombotic therapies for severe sepsis. Prior distributions were defined as severe skeptic (all anti-thrombotic trials or DAA trials); moderate skeptic (anti-thrombotic trials with high risk of death); mild skeptic (DAA trials only); enthusiastic (DAA trials with high risk of death). Results: The total study sample includes 7,683 patients: DAA (N = 3,143); Anti-thrombin-III (N = 2,581); tissue factor pathway inhibitor (N = 1,959). Answer 1: All current probabilities that DAA is not better than the control (except for the enthusiastic analysis) range from 0.14 to 0.48, which strongly suggest the need for a confirmatory trial. Answer 2: The number of patients necessary for the DAA confirmatory trial ranges up to 8,350 for the severe skeptic; 730-810 for moderate skeptic; 550-685 for mild skeptic; and zero for enthusiastic analysis. Conclusions: A confirmatory trial with approximately 600 patients with severe sepsis and high risk of death can provide a convincing answer for both the mild and moderate skeptic physicians concerning the efficacy of DAA in severe sepsis.

KW - Bayesian methodology

KW - Drotrecogin alfa activated

KW - Severe sepsis

UR - http://www.scopus.com/inward/record.url?scp=52949093524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949093524&partnerID=8YFLogxK

U2 - 10.1007/s00134-008-1159-8

DO - 10.1007/s00134-008-1159-8

M3 - Article

C2 - 18504550

AN - SCOPUS:52949093524

VL - 34

SP - 1804

EP - 1811

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 10

ER -